Loading company…
Omnix Medical develops antimicrobial peptide treatments for drug-resistant bacterial infections.
Founded in 2015 and based in Jerusalem, Israel, Omnix Medical develops antimicrobial peptide-based treatments for drug-resistant bacterial infections. In October 2025, it raised USD 25 million in Series C funding co-led by European Innovation Council and Harel Insurance Investments, with other new and returning investors participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in